Status:
UNKNOWN
Microwave Ablation of Primary and Secondary Lung Malignancies
Lead Sponsor:
University of Calgary
Conditions:
Lung Neoplasms
Neoplasm Metastasis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Surgery is the first choice of treatment for early-stage primary pulmonary malignancies, but up to 15% of all patients, and 33% of patients greater than 75 years of age, are not surgical candidate's d...
Eligibility Criteria
Inclusion
- Non-Small Cell Lung Carcinoma and metastatic lesions from lung, colorectal, breast, sarcoma, melanoma
- Patient median estimate survival of \> 1 year, as determined by the treating physician
- ECOG 0-1
- \<5 lesions in either lung
- Limited and/or controlled extra-pulmonary disease - to be determined by multidisciplinary consensus
- Not amenable to surgery, SBRT or chemotherapy (or patient refusal)
- Patient will have documentation by surgeon and/or radiation oncologist that the patient is unamenable to surgery and SBRT
Exclusion
- Lesions \>3cm in size
- Lesions within 1 cm of any critical mediastinal structure (e.g. aorta, main pulmonary arteries, esophagus, phrenic nerve), diaphragm or pleura
- FEV1≤35% predicted
- Clinically significant emphysema (to be determined by the treating physician)
- Previous pneumonectomy
- Inability to tolerate pneumothorax as judged by referring clinician's clinical assessment
- Inability to tolerate general anaesthetic
- Inability to provide informed consent
- INR \> 1.5
- Platelets \< 100
- PTT \> 40
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04369872
Start Date
May 1 2020
End Date
December 31 2022
Last Update
November 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Foothills Medical Centre
Calgary, Alberya, Canada, T2N2T9